Trial result ·
Anakinra versus intramuscular methylprednisolone acetate for gout flares in people with chronic kidney disease (ASGARD): a UK randomised multicentre, double-blind, double-dummy controlled feasibility study with economic, qualitative and safety assessment.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
ASGARD was a feasibility trial of gout flare treatment. The people also had chronic kidney disease. It tested if a double-blind, double-dummy trial could be run. People got anakinra 100 mg daily for 5 days under the skin. Others got methylprednisolone acetate 120 mg into a muscle. Safety, costs and patient views were also gathered.
What they found
The trial did not meet its overall success criteria because of under-recruitment. 21 participants were randomised, and 17 got treatment per protocol. Rules on enrolment, crossover and pain assessments were met. Mean pain fell by 46.8 on a 100 mm scale after 7 days. Anakinra appeared to give a shorter time to pain relief. Participants reported a high burden from questionnaires and delays in treatment.
What it means for patients
The team says a full trial is feasible. They say it can give insight on treatment effects, safety, costs and patient experience. They say better case finding and smoother steps during flares should be explored first.
Why it is not certain yet
Under-recruitment meant the trial missed its overall criteria. A larger trial must confirm the faster pain relief with anakinra. Only 17 of 21 got per protocol treatment. Health resource use was higher by health records.
Source
Anakinra versus intramuscular methylprednisolone acetate for gout flares in people with chronic kidney disease (ASGARD): a UK randomised multicentre, double-blind, double-dummy controlled feasibility study with economic, qualitative and safety assessment.
PubMed · PMID 42816092We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Chronic kidney disease publications